MOSCOW (Sputnik) – The Russian Direct Investment Fund (RDIF) has suspended the supply of the anticovid drug Avifavir abroad due to its high demand in Russia, said the general director of the fund, Kiril Dmitriev.
The antiviral Avifavir , developed by the RDIF together with the pharmaceutical group ChemRar, became the first approved drug against COVID-19 in the world on May 29, 2020.
“We have suspended supplies to foreign markets, due to a very high demand in Russia,” Dmitriev said in an interview with the Rossiya 24 chain.
He added that the RDIF will supply Avifavir again to foreign countries when its production increases and there are sufficient reserves of this drug in Russia.
Dmitriev pointed out that the drug Avifavir has already been supplied to 15 countries around the world.
So far, Russia has registered 2,992,706 cases of coronavirus infection, of which 53,659 are fatal.
Since March 11, the World Health Organization has classified the COVID-19 disease caused by the new SARS-CoV-2 coronavirus detected at the end of 2019 as a pandemic.
Furthermore, Dmitriev stated that RDIF does not expect to make large returns from investments in the fight against COVID-19.
“We do not expect our COVID-19-related investments to generate super-large profits,” Dmitriev said in an interview with Rossiya 24 television channel.
He stressed that the fund always lowers prices to obtain a minimum profit because it understands its social responsibility and that “the main task is to protect people and recover the country’s economic growth.”
“Public money is not simply spent, but is invested with a good return, but this return is reasonable,” he explained.
In early 2020, the RDIF focused its efforts on three main lines of fight against COVID-19: tests, medicines and vaccines.
The fund launched the production of the Russian-Japanese EMG diagnostic system, capable of giving an accurate coronavirus test result in as little as 30 minutes.
Thanks to the EMG system, Russia became one of the world leaders in the number of tests carried out.
The RDIF also launched the production of the anti-COVID drug Avifavir and the Sputnik V vaccine, the first registered in the world against the new infection.